Metformin Fights Vascular Aging by Activating a Novel Cellular Waste-Disposal Pathway
Metformin reduces premature endothelial senescence by boosting 'mitocytosis'—a newly discovered mechanism cells use to eject damaged mitochondria.
Summary
Researchers demonstrated that metformin protects vascular endothelial cells from stress-induced premature senescence (SIPS) by enhancing a recently discovered mitochondrial quality-control process called mitocytosis. Using hydrogen peroxide to trigger oxidative stress in human umbilical vein endothelial cells (HUVECs), the team found metformin reduced senescence markers, restored cell migration and tube formation, and improved mitochondrial membrane potential. Transcriptomic profiling revealed metformin upregulates TSPAN4 and VAMP2—key genes for migrasome formation. When migrasome formation was blocked via siRNA silencing of TSPAN4, metformin's protective effects were abolished, confirming this pathway as central to metformin's vascular benefits.
Detailed Summary
Vascular endothelial cell senescence is a recognized early driver of cardiovascular disease, contributing to impaired barrier function, reduced angiogenesis, and disrupted vascular homeostasis. Stress-induced premature senescence (SIPS)—triggered by oxidative damage, inflammation, or metabolic insults—accelerates these processes independently of replicative aging. Understanding how to pharmacologically counter SIPS is therefore of broad therapeutic interest.
This study used hydrogen peroxide (H₂O₂) to induce SIPS in human umbilical vein endothelial cells (HUVECs) in vitro, creating a reproducible oxidative stress model. Optimal senescence was achieved at 100 µM H₂O₂ for 2 hours, confirmed by elevated SA-β-galactosidase activity and upregulation of the canonical senescence markers p16 and p21. Metformin was then applied across a dose range; 10 mM emerged as optimally protective, significantly reducing SA-β-gal positivity and suppressing p16/p21 at both mRNA and protein levels without cytotoxicity.
Beyond senescence markers, metformin meaningfully restored functional endothelial behaviors. While proliferation (EdU assay) showed a non-significant trend toward recovery, scratch wound healing and tube formation assays demonstrated striking improvements: H₂O₂-treated cells achieved only 29% wound closure at 24 hours versus near-complete closure in metformin-treated cells. Tube node count, mesh formation, and total tube length were all significantly restored. Angiogenic proteins Ang-1 and VEGF were also upregulated by metformin treatment, further supporting functional vascular recovery.
At the mitochondrial level, metformin reduced intracellular ROS, preserved mitochondrial filamentous morphology (preventing fragmentation and perinuclear aggregation), and restored mitochondrial membrane potential (MMP) as measured by JC-1 probes. Transcriptome sequencing (RNA-seq) comparing H₂O₂-treated cells with and without metformin identified 359 differentially expressed genes. KEGG enrichment implicated MAPK, p53, and FoxO signaling pathways, while GO analysis highlighted stress response and cytoskeletal regulation. Crucially, metformin upregulated TSPAN4 and VAMP2—genes encoding proteins essential for migrasome biogenesis and mitocytosis, a novel 2021-described mechanism by which cells physically expel damaged mitochondria via migrasome vesicles rather than degrading them via autophagy.
To validate the functional importance of mitocytosis, the team used siRNA to silence TSPAN4, blocking migrasome formation. This intervention abolished metformin's protective effects against SIPS, confirming that migrasome-mediated mitocytosis is mechanistically required for metformin's benefits in this context. These findings position mitocytosis as a promising therapeutic target for endothelial dysfunction and suggest that metformin's well-documented vascular benefits may be partly mediated through this newly characterized pathway. The work opens avenues for developing interventions that specifically enhance mitocytosis in aging or metabolically stressed vasculature.
Key Findings
- Metformin (10 mM) dose-dependently reduced SA-β-gal activity and suppressed p16/p21 senescence markers in H₂O₂-treated HUVECs.
- Metformin nearly fully restored endothelial cell migration and tube-forming capacity impaired by oxidative stress-induced senescence.
- Metformin preserved mitochondrial membrane potential and filamentous morphology while attenuating intracellular ROS overproduction.
- RNA-seq revealed metformin upregulates TSPAN4 and VAMP2, key genes for migrasome-mediated mitocytosis.
- siRNA knockdown of TSPAN4 abolished metformin's anti-senescence protective effects, confirming mitocytosis as a required mechanism.
Methodology
In vitro SIPS model was established in HUVECs using 100 µM H₂O₂ for 2 hours, validated by SA-β-gal staining and p16/p21 expression. Effects of metformin were assessed via EdU proliferation, scratch wound healing, tube formation, JC-1 MMP assay, DCFH-DA ROS quantification, MitoTracker imaging, and whole-transcriptome RNA sequencing. Mechanistic validation employed siRNA-mediated TSPAN4 knockdown to block migrasome formation.
Study Limitations
The study is entirely in vitro using a single cell type (HUVECs) and a chemical oxidative stress model, limiting direct translation to in vivo or clinical settings. The 10 mM metformin concentration used is substantially higher than typical human plasma levels (~10–40 µM), raising questions about physiological relevance. Mechanistic conclusions rely on siRNA knockdown of a single gene (TSPAN4), and additional in vivo validation of the mitocytosis pathway is needed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: